OBN (UK) Ltd is delighted to announce the winners of the 2018 OBN Awards.
Abingdon, UK, 12 October 2018: – OBN (UK) Ltd, the membership organisation that supports the life sciences industry, is delighted to announce the winners of the 2018 OBN Awards.
The Awards, which are in their 10th year, celebrate the best of UK life sciences – from outstanding scientific innovation within biotech, medtech, digital, synthetic biology, to the companies that support the industry and the fundraisers that make it happen. This years’ event hosted an audience of over 250 life science industry leaders at the Oxford Examination Schools.
John Harris, CEO of OBN, said: “We received an outstanding number of entries this year so competition has been really tough. All of our winners and nominees this year are truly innovative and set a great example to the rest of the industry. We have introduced several new categories this year to reflect industry trends. The turn-out and support we have received is a true reflection of how buoyant our industry is and I would like to thank our sponsors and supporters for helping us make the awards such a great success.”
The winners of the awards are:
Best Start-up Biotech, kindly sponsored by Novo Nordisk
Winner – IGEM Therapeutics
An Immuno-oncology company focused on the development of IgE antibody drugs to fight cancer.
Best Emerging Biotech, kindly sponsored by World Courier
Winner – Blue Earth Diagnostics
A molecular imaging diagnostics company focused on the development and commercialisation of novel PET imaging agents.
Best Established Biotech, kindly sponsored by Horton International
Winner - Oxford BioMedica
Specialising in the development and commercialisation of gene-based medicines.
Best Diagnostic Medtech, kindly sponsored by Penningtons Manches
Winner – DNA Electronics
Breakthrough DNA analysis technology that brings patients the benefits of fast and insightful diagnostics.
Best Imaging Medtech, kindly sponsored by Blue Earth Diagnostics
Winner - Beamline Diagnostics
Developing a biopsy triaging system that can identify healthy and benign tissue specimens with high accuracy within seconds.
Best Innovative Medtech (non-Diagnostic or Imaging), kindly sponsored by James Cowper Kreston
Winner – Invizius
Developing H-Guard™ technology to address the side effects of hemodialysis such as cardiovascular complications.
Best Implementation of Digital Technology for Healthcare
Winner - Ieso Digital Health
Providing online cognitive behavioural therapy (CBT) to treat a range of mental health conditions.
Best Specialist CRO
Winner - Diamond Pharma Services
A leading technical services and consulting group, providing expert support in particular to cell and gene therapy companies.
Best Sector Support Organisation
Winner – UnitDx
A scientific innovation centre for start-ups, SMEs and industrial teams in the Bristol area.
Best Emerging Synthetic Biology Company, kindly sponsored by SynbiCITE
Winner – Evonetix
Revolutionising de novo gene synthesis to facilitate the fast-growing and exciting field of synthetic biology.
The BioSeed ‘One to Watch’ Award, kindly sponsored by Precision for Medicine, Oncology and Rare Disease
Winner - Pragma Therapeutics
Developing innovative therapeutics for the treatment of stress related disorders, in particular post-traumatic stress disorder, and hearing loss.
Special Recognition Award, kindly sponsored by MEPC Milton Park
Winner - James Noble CEO of Adaptimmune and Deputy Chairman of GW Pharmaceuticals for his outstanding contribution to the biotech industry
Outstanding Achievement Award
Winner - Gamma Delta
Developing a pioneering approach to targeted gamma delta T cell therapy which could revolutionise immunotherapy for patients.
ENDS
Contacts:
Event enquiries:
Jane O’Driscoll, Head of Events, OBN - jane.odriscoll@obn.org.uk
Picture requests:
Rebecca Wilkes, Communications & Marketing Co-ordinator, OBN - rebecca.wilkes@obn.org.uk
Media enquiries:
Citigate Dewe Rogerson
Sylvie Berrebi- Sylvie.berrebi@
Shabnam Bashir - shabnam.bashir@
About the OBN Awards – www.obn-awards.com
The OBN Awards, now in its 10th year, celebrates innovation and achievement across the UK Life Sciences Industry. We are proud that the awards remain independent with categories that cover Biotech, Medtech, Synthetic Biology and Digital Health and recognise achievements from emerging R&D companies to large pharma and life sciences investors.
OBN Awards 2018 Independent Judging Panel
John Harris – CEO – OBN
Sue Charles – Managing Partner – Instinctif Partners
Ewa Truchanowicz – Life Sciences Lead – West Midlands Growth Company
Tim Luker – Director External Innovation, Global R&D – Lilly
Sarah Holland – Global Head of Licensing – Lonza
Sian Gill – Partner, Head of Chemical & Life Sciences Team – Venner Shipley
Alan O’Connell – Partner – Serboa Life Sciences
Bill Fleming – Non-Executive Director – OBN
Chris Doherty – Managing Director – Alderley Park
John Chaddock – Vice President Neurology, Site Head – Ipsen
Peter Hamley – Global Head, External Innovation, Drug Discovery Platforms – Sanofi
Jonathan Rohll – Head of Business Information – OBN
Miriam Freiden – Vice President of Search & Evaluation – Novo Nordisk
About OBN – www.obn.org.uk
OBN is the not-for-profit membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors. Our 400+ member companies are located across the Golden Triangle and beyond to, Birmingham, Nottingham, Manchester, the North East and Scotland, and are all benefitting from our networking, partnering, purchasing, advising and advocacy activities.
Further information about OBN’s tailored networking and partnering events, purchasing consortium, advice, consultancy services and advocacy activities is available on OBN’s website www.obn.org.uk.
